Plain-English answer

Public hospital governance in China is the way state-owned or state-controlled hospitals are directed, financed, evaluated, and held accountable. Public hospitals are care providers, referral centers, employers, training bases, research institutions, procurement actors, and local public-service institutions. Their behavior is shaped by government ownership, Communist Party leadership, hospital management, clinical department hierarchy, insurance payment rules, procurement policy, and performance assessment.

Governance model

China's public hospitals sit between administrative hierarchy and market-facing clinical demand. They operate under health commission oversight and local government expectations, but they also depend on service revenue, insurance settlement, department productivity, physician labor, and patient reputation. That mixed position explains many of the tensions in Chinese hospital reform: the state wants public-welfare behavior, patients want access to famous specialists, and hospitals need enough revenue and staff motivation to function.

The older incentive problem was built around drug and service revenue. Because public subsidies were insufficient for many hospitals, drug markups and high-volume services became important to hospital finances. The zero-markup drug policy and later procurement reforms were meant to weaken the link between prescribing and institutional revenue. But removing a revenue source does not by itself create a stable governance model; hospitals still need compensation through service pricing, government subsidy, insurance payment, salary reform, and performance evaluation.

Reform agenda

In June 2021, the State Council released opinions on promoting the high-quality development of public hospitals. The policy framed public hospitals as central to meeting rising demand for medical services and responding to major epidemics and public-health emergencies. It called for reform of personnel management and salary distribution, better evaluation and cultivation of medical workers, stronger hospital operation management, and a modern hospital management system.

The follow-on public hospital high-quality development action plan for 2021 to 2025 emphasized an integrated reform agenda rather than a single administrative fix. It connected public hospital governance with discipline construction, medical quality, operation management, information systems, compensation, and performance assessment. This is the context in which hospital directors now manage: they are expected to improve quality, control cost, maintain public-welfare obligations, prepare for public-health emergencies, and remain financially viable.

Strategic meaning

For a company, research group, or foreign hospital partnership, governance determines who can actually say yes. A department chair may want a product or collaboration, but procurement may block it, the medical insurance office may see no payment route, hospital leadership may avoid compliance risk, and local authorities may prioritize a different reform metric. The formal hospital name is less important than the chain of decision authority.

Public hospital governance also affects evidence generation. A hospital that is under pressure to improve case-mix index, shorten length of stay, reduce drug spending, or strengthen public-health capacity will evaluate projects through those lenses. A device that saves operating-room time, a digital tool that improves follow-up, or a drug that reduces admission may be attractive only if the benefit is visible under the hospital's payment and performance rules. The best analysis maps the governance pressure before designing the access strategy.

Research anchors

Payment and procurement reform layer

Payment, procurement, pricing, and incentive pages

These pages explain how China uses procurement, reimbursement, service pricing, payment reform, and compliance pressure to change healthcare economics.

Volume-Based Procurement in Chinaprocurement and price-control policy instrument Drug Volume-Based Procurement in Chinadrug procurement and price-volume tradeoff Medical Device Volume-Based Procurement in Chinadevice and consumables procurement reform High-Value Medical Consumables Procurement in Chinamedtech-specific procurement pathway National Drug Price Negotiations in ChinaNRDL-linked drug pricing mechanism NRDL Negotiation Strategy for Drug Companiescompany playbook for NRDL access Zero Markup Drug Policy in Chinapublic hospital revenue reform Public Hospital Compensation Reform in Chinapublic hospital incentive and revenue redesign DRG Payment in Chinadiagnosis-related group payment reform DIP Payment Reform in ChinaBig Data Diagnosis-Intervention Packet reform Global Budgets in Chinese Healthcarepayer budget constraint Capitation Pilots in Chinapopulation-based payment experiment Fee-for-Service in Chinapayment method and reform target Essential Medicines in Chinaprimary-care and medicine policy term Centralized Procurement in Chinese Healthcarecentralized purchasing architecture beyond VBP Two-Invoice System in Chinapharmaceutical distribution reform Medical Price Controls in Chinapricing administration across products and services Medical Service Pricing Reform in Chinaservice price reform in public hospitals Provider Incentives in Chinese Hospitalsincentive map around hospitals and physicians Healthcare Anti-Corruption Campaigns in Chinagovernance and procurement risk issue